Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Revance Therapeutics (NQ: RVNC ) 4.310 +0.070 (+1.65%) Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Revance Therapeutics < Previous 1 2 3 4 5 6 7 8 9 Next > SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ROIC, PWUP, RVNC on Behalf of Shareholders November 09, 2024 From Halper Sadeh LLC Via GlobeNewswire Revance Reports Third Quarter 2024 Financial Results, Provides Corporate Update November 07, 2024 From Revance Therapeutics, Inc. Via Business Wire “Top Biotech Opportunities: RVNC, HCTI, GLUE, PRSO, CRDL, Showing Promising Developments” October 28, 2024 Via AB Newswire Topics Artificial Intelligence Exposures Artificial Intelligence SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ZUO, ARC, K, RVNC on Behalf of Shareholders October 18, 2024 From Halper Sadeh LLC Via GlobeNewswire SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates K, RVNC, CPTN on Behalf of Shareholders October 17, 2024 From Halper Sadeh LLC Via GlobeNewswire The Law Offices of Frank R. Cruz Announces Investigation of Revance Therapeutics, Inc. (RVNC) on Behalf of Investors October 17, 2024 From The Law Offices of Frank R. Cruz Via Business Wire INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Revance Therapeutics, Inc. (RVNC) on Behalf of Investors October 15, 2024 From Law Offices of Howard G. Smith Via Business Wire Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Revance Therapeutics, Inc. (RVNC) on Behalf of Investors October 15, 2024 From Glancy Prongay & Murray LLP Via Business Wire SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BTTR, RVNC, ARC, RFL on Behalf of Shareholders September 27, 2024 From Halper Sadeh LLC Via GlobeNewswire REVANCE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Revance Therapeutics, Inc. - RVNC August 15, 2024 From Kahn Swick & Foti, LLC Via Business Wire SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITI, RVNC, BALY, DRQ on Behalf of Shareholders August 13, 2024 From Halper Sadeh LLC Via GlobeNewswire BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Revance Therapeutics, Inc. (Nasdaq – RVNC), Greenbrook TMS, Inc. (OTC – GBNHF), R1 RCM Inc. (Nasdaq - RCM), Enstar Group Limited (Nasdaq – ESGR) August 12, 2024 From Brodsky & Smith LLC Via GlobeNewswire RVNC Investigation: Halper Sadeh LLC Is Investigating Whether the Sale of Revance Therapeutics, Inc. Is Fair to Shareholders August 12, 2024 From Halper Sadeh LLC Via Business Wire Revance Reports Second Quarter 2024 Financial Results, Provides Corporate Update August 08, 2024 From Revance Therapeutics, Inc. Via Business Wire Revance to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024 August 01, 2024 From Revance Therapeutics, Inc. Via Business Wire Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 14, 2024 From Revance Therapeutics, Inc. Via Business Wire Revance to Participate in Upcoming Investor Conferences May 28, 2024 From Revance Therapeutics, Inc. Via Business Wire Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update May 09, 2024 From Revance Therapeutics, Inc. Via Business Wire Revance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical Dystonia May 09, 2024 From Revance Therapeutics, Inc. Via Business Wire Revance to Release First Quarter 2024 Financial Results on Thursday, May 9, 2024 May 02, 2024 From Revance Therapeutics, Inc. Via Business Wire Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting April 12, 2024 From Revance Therapeutics, Inc. Via Business Wire Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) March 27, 2024 From Revance Therapeutics, Inc. Via Business Wire Revance Announces Pricing of $100.0 Million Public Offering of Common Stock March 04, 2024 From Revance Therapeutics, Inc. Via Business Wire Revance Announces Proposed Public Offering of Common Stock March 04, 2024 From Revance Therapeutics, Inc. Via Business Wire Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update February 28, 2024 From Revance Therapeutics, Inc. Via Business Wire Revance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024 February 21, 2024 From Revance Therapeutics, Inc. Via Business Wire Revance to Participate in Upcoming Investor Conferences February 21, 2024 From Revance Therapeutics, Inc. Via Business Wire Revance Receives Permanent J-Code for DAXXIFY® and Announces Publication of DAXXIFY Pivotal Study (ASPEN-1) Results in Neurology® February 02, 2024 From Revance Therapeutics, Inc. Via Business Wire Revance to Participate in the Guggenheim 6th Annual Biotechnology Conference February 01, 2024 From Revance Therapeutics, Inc. Via Business Wire Revance Provides Corporate Update, Preliminary Fourth Quarter and Full Year 2023 Financial Results, and Financial Outlook January 08, 2024 From Revance Therapeutics, Inc. Via Business Wire < Previous 1 2 3 4 5 6 7 8 9 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
